Personalis (PSNL)
(Delayed Data from NSDQ)
$1.30 USD
-0.08 (-5.80%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $1.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.30 USD
-0.08 (-5.80%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $1.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Zacks News
Bausch Health (BHC) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 13.86% and 7.15%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 10.71% and 0.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 1.61% and 8.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Personalis (PSNL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Personalis (PSNL) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 7.94% and 5.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 4.76% and 21.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of -10.53% and 2.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 11.76% and 0.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Personalis (PSNL) Q4 Earnings Expected to Decline
by Zacks Equity Research
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 0.00% and 0.28%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Personalis (PSNL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 12.82% and 2.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Personalis (PSNL) Q2 Earnings Expected to Decline
by Zacks Equity Research
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 21.62% and 2.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Personalis (PSNL) Q1 Earnings Expected to Decline
by Zacks Equity Research
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Personalis (PSNL) Stock Jumps 7.9%: Will It Continue to Soar?
by Zacks Equity Research
Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
What's in Store for Zomedica (ZOM)This Earnings Season?
by Zacks Equity Research
Zomedica (ZOM) may provide an update on Truforma commercialization progress when it reports fourth-quarter 2020 results.
What's in Store for Mallinckrodt (MNKKQ)This Earnings Season?
by Zacks Equity Research
Negative impact of COVID-19 is likely to have hurt sales of Mallinckrodt (MNKKQ) during the fourth quarter. Investors are likely to focus on bankruptcy proceedings during the earning call.
Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 10.00% and 2.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Personalis (PSNL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Personalis (PSNL) Looks Good: Stock Adds 8% in Session
by Zacks Equity Research
Personalis (PSNL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 14.71% and 14.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA Advisory Committee Recommends Mallinckrodt's Trelipressin
by Zacks Equity Research
The Cardiovascular and Renal Drugs Advisory Committee of the FDA votes in favor of Mallinckrodt's (MNK) investigational agent, terlipressin, to treat adults with hepatorenal syndrome type 1.
Personalis, Inc. (PSNL) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Personalis, Inc. (PSNL).